Education
About Us
Working with TipRanks
Follow Us
Imunon (IMNN)
NASDAQ:IMNN
IMNN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.70 - $41.22
Previous CloseN/A
Volume151.93K
Average Volume (3M)111.49K
Market Cap
$12.98M
Enterprise Value$11.79M
Total Cash (Recent Filing)$4.73M
Total Debt (Recent Filing)$1.19M
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Nov 17, 2025EPS Estimate
-1.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding2,521,206
10 Day Avg. Volume217,806
30 Day Avg. Volume111,491
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue16.22
Enterprise Value/Gross Profit-62.63
Enterprise Value/Ebitda-0.78
Forecast
1Y Price Target
$210.00Price Target Upside4009.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Regulatory AdvantagesIMNN-001 has orphan status in the US and EU, providing regulatory benefits and market exclusivity.
Strategic FinancingImunon has secured near-term financing through a private placement, providing essential capital needed to cover initiation-related costs of the OVATION study.
Therapeutic EfficacyIMNN-001 therapy led to consistent and clinically meaningful improvements in key endpoints across treatment groups, including a 13-month increase in overall survival and a 3-month increase in progression-free survival compared to standard care.
Bears Say
Funding ChallengesThe company is in active discussions with potential partners to secure essential capital for the Phase 3 OVATION 3 study.
Regulatory RiskThe trial's design includes interim analyses which could lead to an earlier active readout, potentially accelerating the approval process.
Trial ComplexityAdditional trial sites are expected to activate shortly, with an estimated total of ~45 sites, indicating a broad and robust study.
Imunon News
IMNN FAQ
What was Imunon’s price range in the past 12 months?
Imunon lowest stock price was $4.70 and its highest was $41.22 in the past 12 months.
What is Imunon’s market cap?
Imunon’s market cap is $12.98M.
When is Imunon’s upcoming earnings report date?
Imunon’s upcoming earnings report date is Nov 17, 2025 which is in 53 days.
How were Imunon’s earnings last quarter?
Imunon released its earnings results on Aug 05, 2025. The company reported -$1.87 earnings per share for the quarter, beating the consensus estimate of -$4.141 by $2.271.
Is Imunon overvalued?
According to Wall Street analysts Imunon’s price is currently Undervalued.
Does Imunon pay dividends?
Imunon does not currently pay dividends.
What is Imunon’s EPS estimate?
Imunon’s EPS estimate is -1.49.
How many shares outstanding does Imunon have?
Imunon has 2,521,206 shares outstanding.
What happened to Imunon’s price movement after its last earnings report?
Imunon reported an EPS of -$1.87 in its last earnings report, beating expectations of -$4.141. Following the earnings report the stock price went down -4.75%.
Which hedge fund is a major shareholder of Imunon?
Currently, no hedge funds are holding shares in IMNN
Imunon Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$210.00 (4009.59% Upside)
$210.00 (4009.59% Upside)
Crowd Wisdom
Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.96%
12-Months-Change
Fundamentals
Return on Equity
-491.97%
Trailing 12-Months
Asset Growth
-9.32%
Trailing 12-Months
Company Description
Imunon
Imunon, Inc. (IMNN) is a biotechnology company focused on the development and commercialization of innovative therapies that leverage its proprietary platform technologies. The company's primary areas of focus include oncology and infectious diseases, with a core emphasis on developing advanced DNA-based immunotherapies and vaccine solutions. Imunon aims to address unmet medical needs by providing effective and safe treatment options for patients worldwide.
IMNN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
IMUNON's earnings call highlighted significant progress in its ovarian cancer treatment and the strong start of the Phase III OVATION 3 trial. The company is effectively managing costs and enhancing shareholder value through a stock dividend. However, it faces challenges in the capital markets, requiring ongoing efforts to secure additional funding.View all IMNN earnings summariesTechnical Analysis
Lite Strategy
―
Phio Pharmaceuticals
―
Cocrystal Pharma
―
BioRestorative Therapies
―
IN8bio
―
Ownership Overview
14.89% Insiders
4.95% Mutual Funds
0.11% Other Institutional Investors
79.81% Public Companies and Individual Investors
Options Prices
Currently, No data available
---